在阿尔茨海默氏症中,基因组脱乙酶2:用于治疗向的全面分子蓝图
Kavuma Asadi1, Radha K1, Sairaj Satarker2
1KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Green Fields, Vaddeswaram, Andhra Pradesh, 522302, India.
Molecular neurobiology
|August 8, 2025
概括
海斯脱乙酶2 (HDAC2) 在阿尔茨海默病 (AD) 发病过程中发挥着关键作用,导致神经毒性,突触功能障碍和标志性病理. 调节HDAC2为AD提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是认知能力下降的主要原因,其特点是突触功能障碍和神经退行.
- 人们越来越认识到表观遗传失调是AD复杂病理学的重要因素.
- 海斯脱乙酶2 (HDAC2) 参与了与AD相关的各种神经毒性过程.
研究的目的:
- 审查HDAC2在驱动AD相关神经毒性过程中的多方面的作用.
- 探索通过失调的HDAC2活动导致AD特征的途径.
- 总结目前针对AD的HDAC抑制的治疗策略.
主要方法:
- 对阿尔茨海默病中HDAC2研究的综合文献综述.
- 对将HDAC2与突触功能障碍,粉样β斑块和团联系起来的分子通路的分析.
- 检查HDAC2,神经炎症和氧化应激之间的相互作用.
主要成果:
- 异常的HDAC2活性是突触功能障碍,粉样β斑块积累和AD中神经纤维状结形成的关键驱动因素.
- 失调的HDAC2有助于AD大脑微环境中的神经炎症和氧化应激.
- 目前的HDAC抑制策略面临局限性,需要进一步研究有效的治疗方法.
结论:
- HDAC2是阿尔茨海默氏病发病过程中的关键表观遗传调节剂.
- 准HDAC2是一个有前途的治疗途径,但选择性调节至关重要.
- 未来的研究应该专注于开发安全有效的HDAC2-调节AD治疗方法.
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
Spreading of Chromatin Modifications
8.5K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.5K


